Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Patheon | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Patheon

Revenues up 10% with continued growth across sterile and oral solid dose forms

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Patheon

4Q Revenues: $510 million (+10%)

4Q Earnings: $44.1 million (earnings were $147.4 million 4Q15)

FY Revenues: $1.9 billion (+5%)

FY Earnings: $31.7 million (earnings were $138.4 million FY15)

Comments: Despite temporary closures at two sites, the DPS segment sales were $298 million with continued volume growth and demand across sterile and oral solid dose forms. PDS sales were $60 million, primarily driven by strong demand for sterile and low-solubility services. The Drug Substance segment sales were $152 million with continued strong demand for biologics services, which now represents approximately 50% of segment revenues.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters